DOI QR코드

DOI QR Code

A Case of Severe Coronary Spasm Associated with 5-Fluorouracil Chemotherapy

  • Kim, Sang-Min (Department of Internal Medicine, Cardiovascular Center, Inje University Seoul Paik Hospital) ;
  • Kwak, Cheol-Hoon (Department of Internal Medicine, Cardiovascular Center, Inje University Seoul Paik Hospital) ;
  • Lee, Bo-Ra (Department of Internal Medicine, Cardiovascular Center, Inje University Seoul Paik Hospital) ;
  • Kim, Seong-Beom (Department of Internal Medicine, Cardiovascular Center, Inje University Seoul Paik Hospital) ;
  • Sir, Jung-Ju (Department of Internal Medicine, Cardiovascular Center, National Medical Center) ;
  • Cho, Wook-Hyun (Department of Internal Medicine, Cardiovascular Center, Inje University Seoul Paik Hospital) ;
  • Choi, Suk-Koo (Department of Internal Medicine, Cardiovascular Center, Inje University Seoul Paik Hospital)
  • Published : 2012.09.01

Abstract

Cardiotoxicity associated with 5-fluorouracil (FU) is an uncommon, but potentially lethal, condition. The case of an 83-year-old man with colon cancer who developed chest pain during 5-FU infusion is presented. The electrocardiogram (ECG) showed pronounced ST elevation in the lateral leads, and the chest pain was resolved after infusion of nitroglycerin. A coronary angiogram (CAG) revealed that the patient had significant atherosclerosis in the proximal left circumflex artery. Coronary artery spasm with fixed stenosis was considered, and a drug-eluting stent was implanted. After 8 hours, the patient complained of recurring chest pain, paralleled by ST elevation on the ECG. The chest pain subsided after administration of intravenous nitroglycerin followed by sublingual nifedipine. Repeated CAG showed patency of the previous stent. This case supports the vasospastic hypothesis of 5-FU cardiac toxicity, indicating that a calcium channel blocker may be effective in the prevention or treatment of 5-FU cardiotoxicity.

Keywords

References

  1. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58:487-493. https://doi.org/10.1007/s00280-005-0178-1
  2. Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M. High incidence of angina pectoris in patients treated with 5-fluorouracil: a planned surveillance study with 102 patients. Oncology 2003;65:108-112. https://doi.org/10.1159/000072334
  3. Robben NC, P ippa s AW, Moore JO. The sy nd rome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1993;71:493-509. https://doi.org/10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C
  4. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-f luorouracil alone or in combination with cisplatin. Cancer 1990;65:885-889. https://doi.org/10.1002/1097-0142(19900215)65:4<885::AID-CNCR2820650410>3.0.CO;2-H
  5. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1990;1:409-414. https://doi.org/10.1093/oxfordjournals.annonc.a057793
  6. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7:509-514. https://doi.org/10.1200/JCO.1989.7.4.509
  7. Kleiman NS, Lehane DE, Geyer CE Jr, Pratt CM, Young JB. Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med 1987;82:566-568. https://doi.org/10.1016/0002-9343(87)90465-7
  8. Patel B, Kloner RA, Ensley J, Al-Sarraf M, Kish J, Wynne J. 5-fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-243. https://doi.org/10.1097/00000441-198710000-00004
  9. Baker WP, Dainer P, Lester WM, Marty AM, Blair TP. Ischemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986;57:497-498. https://doi.org/10.1016/0002-9149(86)90788-5
  10. Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and longterm follow-up. Jpn J Clin Oncol 2005;35:265-270. https://doi.org/10.1093/jjco/hyi071

Cited by

  1. Fluorouracil vol.1431, pp.1, 2012, https://doi.org/10.1007/s40278-012-0066-5
  2. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity vol.15, pp.None, 2014, https://doi.org/10.1186/2050-6511-15-47
  3. Coenzyme Complex Decreased Cardiotoxicity When Combined with Chemotherapy in Treating Elderly Patients with Gastrointestinal Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/apjcp.2015.16.9.4045
  4. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity vol.31, pp.4, 2012, https://doi.org/10.3904/kjim.2016.017
  5. 5-fluorouracil and cardiotoxicity: a review vol.10, pp.None, 2012, https://doi.org/10.1177/1758835918780140
  6. Mitochondrial Dynamics in Rat Heart Induced by 5-Fluorouracil vol.24, pp.None, 2012, https://doi.org/10.12659/msm.910537
  7. Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society vol.26, pp.1, 2018, https://doi.org/10.4250/jcu.2018.26.1.1
  8. Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions vol.14, pp.2, 2019, https://doi.org/10.15420/icr.2019.12
  9. Fluorouracil-induced Takotsubo cardiomyopathy causing cardiogenic shock: a case report of clinical and acute cardiac magnetic resonance imaging features vol.3, pp.4, 2012, https://doi.org/10.1093/ehjcr/ytz146
  10. S1-induced vasospastic angina—diagnostic utility of Holter ECG: a report of a case vol.6, pp.1, 2012, https://doi.org/10.1186/s40792-020-00975-x
  11. Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study vol.26, pp.3, 2012, https://doi.org/10.1002/onco.13536